Avacta Group PLC Director's Dealing (1878N)

TIDMAVCT

RNS Number : 1878N

Avacta Group PLC

21 October 2016

21 October 2016

Avacta Group plc

("Avacta", "the Group" or "the Company")

Director's Dealing

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics, research and diagnostic reagents, announces that Dr. Mike Owen, a Non-Executive Director of the Group, has purchased today 7,763 Ordinary Shares of 10p each in the Group at a price of 90.0 pence per share.

Following this transaction, Dr Owen's total interest in the Group is 7,763 Ordinary Shares of 10p each, representing less than 0.1% of Avacta's issued share capital.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Enquiries:

 
     Avacta Group plc                              Tel: +44 (0) 
      Alastair Smith, Chief Executive               844 414 0452 
      Officer                                       www.avacta.com 
      Tony Gardiner, Chief Financial 
      Officer 
     finnCap Ltd                                   Tel: +44 (0) 
      Geoff Nash / Giles Rolls - Nominated          207 220 0500 
      Adviser                                       www.finncap.com 
      Tim Redfern / Alice Lane - Corporate 
      Broking 
                                                    Tel: +44 (0) 
      WG Partners                                   203 705 9318 
      David Wilson                                  Tel: +44 (0) 
      Nigel Barnes                                  203 705 9217 
      Claes Spang                                   www.wgpartners.co.uk 
     Media Enquiries                               Tel: +44 (0) 
      FTI Consulting                                203 727 1000 
      Simon Conway / Natalie Garland-Collins        [e-mail] 
 

Notes to Editors

Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $75bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets to enable diagnostics, research assays and therapeutics.

Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
     1.       Details of the person discharging managerial 
               responsibilities / person closely associated 
-------  ------------------------------------------------------------------------------- 
     a)       Name                                 Dr Mike Owen 
-------  -----------------------------------  ------------------------------------------ 
     2.       Reason for the Notification 
-------  ------------------------------------------------------------------------------- 
     a)       Position/status                      Non - Executive Director 
-------  -----------------------------------  ------------------------------------------ 
     b)       Initial notification/Amendment            Initial notification 
-------  -----------------------------------  ------------------------------------------ 
 3.           Details of the issuer, emission allowance 
               market participant, auction platform, auctioneer 
               or auction monitor 
-------  ------------------------------------------------------------------------------- 
     a)       Name                                 Avacta Group Plc 
-------  -----------------------------------  ------------------------------------------ 
     b)       LEI                                  n/a 
-------  -----------------------------------  ------------------------------------------ 
 4.           Details of the transaction(s): section to 
               be repeated for (i) each type of instrument; 
               (ii) each type of transaction; (iii) each 
               date; and (iv) each place where transactions 
               have been conducted 
-------  ------------------------------------------------------------------------------- 
     a)       Description of                             Ordinary shares 
               the Financial                               of 10p 
               instrument, type 
               of instrument 
------- 
              Identification                       GB00BYYW9G87 
               code 
-------  -----------------------------------  ------------------------------------------ 
     b)       Nature of the                              Purchase of 10p Ordinary Shares 
               transaction 
-------  -----------------------------------  ------------------------------------------ 
     c)       Price(s) and                              Price(s)          Volume(s) 
               volume(s)                            ----------------  -------------- 
                                                         90.0 pence        7,763 
                                                    ----------------  -------------- 
-------  -----------------------------------  ------------------------------------------ 
     d)       Aggregated information: 
                *    Aggregated volume               See above 
 
 
                *    Price 
-------  -----------------------------------  ------------------------------------------ 
     e)       Date of the transaction              21 October 2016 
-------  -----------------------------------  ------------------------------------------ 
     f)       Place of the                         London Stock Exchange, AIM 
               transaction                          Market (XLON) 
-------  -----------------------------------  ------------------------------------------ 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLLFVIIELLFIR

(END) Dow Jones Newswires

October 21, 2016 06:39 ET (10:39 GMT)